Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs AMLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AMLX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–1 Matrix Metrics)

AMLX Overall Winner 6-Pillar Tally: NTLA 2 – 4 AMLX Matrix Metrics: NTLA 1 – 8 AMLX

As of Nov 16, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas AMLX carries 58.8/100 (HOLD) at $28.23 (2.8x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: AMLX earns the overall head-to-head edge with a stronger Unified Composite Score (58.8/100 HOLD vs. NTLA 49.9/100 HOLD) and 1.16β · 59% Vol risk profile, whereas NTLA leads top-line expansion (-48.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile AMLX is in a Breakdown options structure phase (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs AMLX
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $11.58 · SMA50: $11.86
AMLX NASDAQ Head-to-Head Winner
Amylyx Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.23
-6.78% 1D
Market Cap $3.8B
TTM Revenue N/A
Forward P/E 2.8x
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
58.8 / 100 HOLD
Tech 47.0 Fund 52.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $28.99 · SMA50: $29.53

6-Pillar Scorecard Institutional Category Breakdown (NTLA 2 – 4 AMLX)

Columns: Metric · NTLA · AMLX
1. Valuation Multiples AMLX
Forward P/E N/M 2.8x
Trailing P/E N/M 2.8x
PEG Ratio N/M N/M
EV / Revenue 29.1x N/M
2. Growth & Scale NTLA
Revenue Growth (YoY) -48.0% -99.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M N/A
Market Cap $1.5B $3.8B
3. Profitability & Quality AMLX
Gross Margin N/A N/A
Operating Margin -826.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.6% -30.1%
4. Balance Sheet & Cash Flow AMLX
Cash Generation (TTM) -$358M -$130M
Cash Flow Margin N/A N/A
Net Cash / Leverage $74M Net Debt (0.38x D/E) $235M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AMLX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 101.3% (78th %ile) 61.4% (10th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (1) vs AMLX (8)
Institutional Metric NTLA AMLX Criterion Row Edge
Market Capitalization
Scale
$1.5B $3.8B Larger Scale AMLX
Trailing P/E Ratio
Valuation
N/M 2.8x Lower Multiple AMLX
Forward P/E Ratio
Valuation
N/M 2.8x Lower Multiple AMLX
Revenue Growth (YoY)
Growth
-48.0% -99.6% Higher Growth NTLA
Operating Margin (TTM)
Profitability
-826.0% 0.0% Higher Margin AMLX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.6% -30.1% Higher ROE AMLX
52-Week Range Position
Momentum
20% ($8–$18) 57% ($11–$41) Stronger Trend AMLX
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 1.16β · 59% Vol Lower Realized Risk AMLX
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 58.8 / 100 (HOLD) Higher Composite AMLX
Trailing 12M Revenue (USD)
Operating Scale
$53M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$130M ($235M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AMLX +19.62 pp
NTLA: -12.43% · AMLX: +7.19%
3M Horizon NTLA +5.79 pp
NTLA: -13.79% · AMLX: -19.58%
6M Horizon AMLX +140.76 pp
NTLA: -21.2% · AMLX: +119.56%
1Y Horizon AMLX +111.99 pp
NTLA: +15.34% · AMLX: +127.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue AMLX Revenue NTLA Op. Margin AMLX Op. Margin Margin Leader
FY2018 $30M N/A -298.6% N/A NTLA
FY2019 $40M N/A -246.8% N/A NTLA
FY2020 $60M N/A -235.5% N/A NTLA
FY2021 $30M $0M -810.4% -29013.3% NTLA
FY2022 $50M $20M -879.0% -905.7% NTLA
FY2023 $40M $380M -1420.5% 10.2% AMLX
FY2024 $60M $90M -923.1% -360.2% AMLX
FY2025 $70M N/A -651.7% N/A NTLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMLX BREAKDOWN
61d in phase · OBV ACCUMULATION
Current IV 61.4%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact AMLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
AMLX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs AMLX Key Questions & Quantitative Answers

As of Nov 16, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas AMLX carries 58.8/100 (HOLD) at $28.23 (2.8x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: AMLX earns the overall head-to-head edge with a stronger Unified Composite Score (58.8/100 HOLD vs. NTLA 49.9/100 HOLD) and 1.16β · 59% Vol risk profile, whereas NTLA leads top-line expansion (-48.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile AMLX is in a Breakdown options structure phase (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NTLA leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with AMLX at -99.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while AMLX shifted +350.0%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AMLX.

AMLX screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas AMLX trades at 2.8x Forward P/E, 2.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus AMLX (-30.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, AMLX carries 61.4% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.16β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.